Phase 1: Discovery Governance - Enforcing Scientific Truth.
Stop wasting capital on non-reproducible leads. We provide the on-ground technical proxy required to ensure your early-stage science is audit-ready, scalable, and defensible.
1. The Pharma Governance Pillars
Regardless of the molecule type, these three enforcement layers protect your investment.
Assay Reproducibility Forensics:
We don’t just "monitor" labs; we challenge their protocols. We verify that discovery data generated in India will replicate perfectly in your home labs in the US or EU, eliminating the "reproducibility crisis" before it hits your budget.
Technical IP Firewall:
High scientist turnover in CROs is an IP leak risk. We document proprietary "know-how" and perform weekly audits of Electronic Lab Notebooks (ELN) to
ensure your IP stays with you, not the employee who leaves.
Lead-to-CMC Foresight:
We audit discovery routes specifically to identify downstream manufacturing "showstoppers"—such as hazardous chemistries or unstable cell lines—while the cost of pivot is still low.
2. Modality-Specific Technical Muscle
Instruction for Developer: These sub-sections highlight Aventiq’s ability to govern complex science.
Small Molecules (NCEs & Complex Generics)
MedChem Stewardship: Oversight of Hit-to-Lead (H2L), SAR (Structure-Activity Relationship) studies, and scaffold hopping to build non-infringing, high-value IP portfolios.
Route Scouting & Optimization: Identifying the most cost-effective synthetic pathways early while eliminating reagents that are restricted by global ESG or regulatory standards.
Polymorph Screening Oversight: Ensuring early-stage salt and polymorph screening is robust enough to prevent "late-stage" stability failures.
Biologics & Biosimilars
Cell Line Development (CLD) Governance: Cell Line Development (CLD) Governance:
Route Scouting & Optimization: Identifying the most cost-effective synthetic pathways early while eliminating reagents that are restricted by global ESG or regulatory standards.
Analytical Comparability: Oversight of early-stage characterization (Mass Spec, Glycan profiling) to ensure the molecule is functionally equivalent to the target or innovator profile.
ADCs (Antibody-Drug Conjugates)
The "Interface Guard": Computational and bench-top modeling of the antibody-linker-payload intersection. We verify molecular stability and "drug-to-antibody ratio" (DAR) consistency before you move to expensive conjugation runs.
Cytotoxic Payload Vetting: Ensuring the potency and purity of the small-molecule payload meets oncological efficacy standards.
Advanced Therapies (Cell & Gene / mRNA)
Target Fidelity Verification: Independent vetting of genomic target identification and CRISPR/mRNA sequence integrity.
Viral Vector Stewardship: Oversight of early-stage vector design and titer-optimization protocols to ensure the science is translatable to clinical manufacturing.
3. The Aventiq Discovery Dashboard
We deliver the transparency Western executives require:
ELN Compliance Rate
Real-time tracking of documentation hygiene.
IP Transfer Logs
Weekly verification of data sovereignty.
Milestone Truth-Check
Independent confirmation of "Go/No-Go" data points.
Phase 2 — Development & CMC Governance (Pharma & Biopharma)
Phase 2: Development & CMC Governance — Beyond the "Guided Tour."
Quality in India is often performative. We provide the on-ground technical enforcement to ensure your scale-up is defined by 24/7 data integrity, not "paper-only" compliance.
1. The CDMO Governance Mandate
When you outsource to an Indian CDMO, you aren't just buying capacity—you are inheriting their risks. We mitigate those risks through direct, unannounced intervention.
2 AM Unannounced Walk-throughs:
Most quality drift and "corner-cutting" happens on the night shift. We don’t wait for scheduled audits; we walk into the manufacturing suites unannounced to verify that the Batch Manufacturing Record (BMR) is being followed in real-time, ensuring your product is handled exactly as the protocol demands.
Impurity Forensic Mapping (ICH M7):
We oversee the detection and control of mutagenic impurities, including Nitrosamines, at the source. We catch structural alerts during process development so your program doesn't face a catastrophic regulatory rejection 12 months later.
The "Shadow" Supply Chain Audit:
We vet your vendor’s vendors. We perform technical audits on the suppliers of your starting materials, specialized reagents, and catalysts to prevent "hidden" impurities from entering your GMP process.
2. Modality-Specific CMC Enforcement
Small Molecules (NCEs & Complex Generics)
HPAPI & OEB 4-6 Containment:
Independent verification of isolator integrity, pressure differentials, and cleaning validation for highly potent APIs. We ensure that "cross-contamination" is a zero-risk event.
Polymorph & Chiral Stability:
Oversight of crystallization kinetics and solid-state characterization (XRPD/DSC) to ensure your molecule maintains the correct crystalline form through large-scale drying and milling operations.
Process Stress-Testing (PAR/NOR):
We demand Proven Acceptable Range (PAR) testing. We don't just accept a single "golden batch"; we ensure the process is robust enough to handle the minor fluctuations of industrial-scale manufacturing.
Biologics, ADCs & Biosimilars
Upstream/Downstream Stewardship:
Oversight of bioreactor parameters (pH, DO, Temp) and purification yields. We ensure that "Process Drift" doesn't compromise the glycan profile or potency of your biologic.
Analytical Comparability Forensics:
We audit the raw data from HPLC, CE-SDS, and Bioassays to ensure the product manufactured at the CDMO is a perfect match for your clinical or reference standard.
Cold-Chain Governance:
We audit the "Last Mile" of the manufacturing floor—verifying that temperature-sensitive drug substances are moved and stored with 100% data-logged continuity.
3. Tech-Transfer & Intellectual Security
The greatest risk during tech-transfer is the loss of "Tribal Knowledge" when CDMO staff turnover occurs.
Capturing the "Invisible" SOP:
We document the subtle nuances of the process—the specific ramp rates and "operator feel"—that are often missing from the official Tech-Transfer Dossier.
Person-in-Plant (PIP) Advocacy:
Our technical leads sit in the facility during the manufacture of Engineering and Validation batches. We act as your on-ground decision-makers to solve deviations in minutes, not days.
Firewalled Knowledge Vault:
We maintain an independent, secure repository of your process parameters. If you ever need to move your molecule to a new CDMO, Aventiq holds the "Technical Key" to make that move seamless.
4. The CMC Governance Dashboard
Real-time metrics for the Global VP:
Right-First-Time (RFT) Rate:
Tracking success across validation batches.
Open Deviation Aging:
Ensuring the CDMO isn't "burying" technical issues.
Audit Trail Reviews:
Weekly verification of raw instrument data (HPLC/GC) to prevent "trial injections" or data manipulation.
Phase 3 - Clinical & Regulatory Governance
Phase 3: Clinical & Regulatory Governance — Defensible Data for Global Filings.
Indian clinical data is under intense global scrutiny. We provide the on-ground verification to ensure your study results are 100% ALCOA+ compliant and ready for FDA, EMA, or PMDA submission.
1. THE Clinical "TRUTH-CHECK"
We don't just manage the CRO; we audit the source. We ensure the data in your dossier matches the reality on the ground.
Source Data Verification (SDV) Forensics:
We go beyond the electronic Case Report Forms (eCRF). Our auditors visit clinical sites to verify original patient records, dosing logs, and informed consent documents. We find the "human errors" before regulatory inspectors do.
Bio-Analytical Sample Integrity:
The greatest risk in Indian clinical trials is sample degradation during transit or storage. We perform unannounced checks on freezer logs, "chain-of-custody" documentation, and transport conditions to ensure your endpoints aren't compromised by logistics.
The "Audit-Ready" Site Prep:
We treat every day like an inspection day. We perform mock-audits of clinical sites and bio-analytical labs to ensure the staff is trained and the documentation is robust enough to survive a "Level 3" regulatory inquiry.
2. Modality-Specific Regulatory Enforcement
Small Molecules & Complex Generics
BA/BE Study Oversight:
Rigorous monitoring of Bioavailability and Bioequivalence studies, ensuring 100% traceability of the Reference Listed Drug (RLD) and the test batch. We prevent "sample switching" and verify the authenticity of the bio-analytical chromatograms.
PK/PD Data Integrity:
Direct oversight of pharmacokinetic and pharmacodynamic data capture to ensure the mathematical models are based on "Clean" raw data.
Biologics, ADCs & Biosimilars
Immunogenicity Monitoring: Independent vetting of anti-drug antibody (ADA) assay validation and clinical sample testing. We ensure your biologic’s safety profile is accurately captured.
Comparability Bridging:
Vector Shedding & Safety Governance: Oversight of specialized clinical protocols for gene therapy site safety and environmental monitoring.
Advanced Therapies (CGT / mRNA)
Vector Shedding & Safety Governance
Oversight of specialized clinical protocols for gene therapy site safety and environmental monitoring.
Precision Patient Selection:
Verification of genomic screening and enrollment criteria to ensure your clinical endpoints are evaluated in the correct patient population.
3. Regulatory Defense & Dossier Governance
Translating Indian execution into Western expectation.
CMC-to-Clinical Alignment:
We ensure that the batch used in your clinical trials is a perfect technical match for the process described in your CMC dossier. No "late-stage surprises" during the final review.
483 & Query Remediation:
If a regulatory agency issues a Query or a Form 483, we are on-ground within 24 hours to lead the technical remediation and draft the response based on verified, forensic facts.
Global Dossier Stewardship:
We "bridge the gap" between local Indian lab reports and the specific granularity required for FDA (NDA/ANDA) and EMA (MAA) submissions.
4. The Final Gate(Submission Readiness)
Before you file, we provide the "Aventiq Green Light" based on:
100% Audit Trail Review of all bio-analytical laboratory instruments.
Verified Chain of Custody for every clinical sample from site to lab.
Dossier Consistency Check (Cross-referencing Technical, Manufacturing, and Clinical data).
Phase 4: Signature High-Value Services
The "Premium" Technical Interventions This section provides elite, rapid-response solutions for the most critical bottlenecks in the drug development lifecycle.
1. Rescue Operations (Crisis Management)
Rapid Diagnosis:
We provide an independent audit and turnaround of troubled CRO/CDMO relationships or programs that have gone "silent."
Technical Remediation:
Immediate deployment for corrective action plans (CAPA), regulatory query responses (Form 483), and project re-baselining to save critical market-entry timelines.
2. Integrated IND Package (Turnkey Strategy)
End-to-End Accountability:
Strategic oversight from lead optimization through the final IND filing.
Regulatory-Ready Data:
We deliver a complete, single-point accountability data package engineered for aggressive and predictable global timelines.
3. IP & Tech Transfer Safeguard (Value Protection)
Technical Firewall:
We ensure absolute IP security during cross-border transfers by documenting "tribal know-how" and verifying that proprietary processes remain your exclusive asset.
Integrity Enforcement:
Continuous ALCOA+ data integrity audits to ensure full traceability and IP sovereignty.
4. Supply Chain Redundancy (De-Risking)
"Plan B" Resilience:
We pre-qualify secondary sources for critical intermediates or APIs to prevent single-point-of-failure disruptions.
Supply Chain Continuity:
Developing a resilient commercial and clinical supply chain through independent site audits and "Person-in-Plant" representation.
